Hypoglycemia in type 2 diabetes: a critical review

Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2004-12, Vol.58 (10), p.551-559
Hauptverfasser: Murata, Glen H., Duckworth, William C., Hoffman, Richard M., Wendel, Christopher S., Mohler, M. Jane, Shah, Jayendra H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 559
container_issue 10
container_start_page 551
container_title Biomedicine & pharmacotherapy
container_volume 58
creator Murata, Glen H.
Duckworth, William C.
Hoffman, Richard M.
Wendel, Christopher S.
Mohler, M. Jane
Shah, Jayendra H.
description Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.
doi_str_mv 10.1016/j.biopha.2004.09.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67160977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332204001465</els_id><sourcerecordid>67160977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMozjj6D0S60V3rSz-SxoUggzrCgBtdhzR51QzttCYdpf_elhbcuXqbcy_3HUIuKUQUKLvdRYVt2k8VxQBpBCICoEdkSUUGIQPgx2QJPEvCJInjBTnzfgcAGUvyU7KgWZYLYPGSxJu-bT6qXmNtVWD3Qde3GMSBsarADv1doALtbGe1qgKH3xZ_zslJqSqPF_Ndkfenx7f1Jty-Pr-sH7ahTgR0ITVlKgwqw7gygieUo8qLVKdapIVhWNKCIVM808iRoRYKNI9FVoIANJAnK3Iz9bau-Tqg72RtvcaqUntsDl4yThkIzgcwnUDtGu8dlrJ1tlaulxTk6Eru5ORKjq4kCDm4GmJXc_-hqNH8hWY5A3A9A8oP75dO7bX1fxwb1Yqx6H7icLAxGHLSa4t7jcY61J00jf1_yS8hf4i_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67160977</pqid></control><display><type>article</type><title>Hypoglycemia in type 2 diabetes: a critical review</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</creator><creatorcontrib>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</creatorcontrib><description>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2004.09.001</identifier><identifier>PMID: 15589062</identifier><identifier>CODEN: BIPHEX</identifier><language>eng</language><publisher>Paris: Elsevier SAS</publisher><subject>Biological and medical sciences ; Circadian Rhythm - physiology ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes mellitus, type II ; Humans ; Hypoglycemia ; Hypoglycemia - blood ; Hypoglycemia - complications ; Hypoglycemia - physiopathology ; Hypoglycemic agents ; Insulin ; Medical sciences ; Pharmacology. Drug treatments ; Risk factors</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2004-12, Vol.58 (10), p.551-559</ispartof><rights>2004 Elsevier SAS</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</citedby><cites>FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2004.09.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16332291$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15589062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murata, Glen H.</creatorcontrib><creatorcontrib>Duckworth, William C.</creatorcontrib><creatorcontrib>Hoffman, Richard M.</creatorcontrib><creatorcontrib>Wendel, Christopher S.</creatorcontrib><creatorcontrib>Mohler, M. Jane</creatorcontrib><creatorcontrib>Shah, Jayendra H.</creatorcontrib><title>Hypoglycemia in type 2 diabetes: a critical review</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</description><subject>Biological and medical sciences</subject><subject>Circadian Rhythm - physiology</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetes mellitus, type II</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - blood</subject><subject>Hypoglycemia - complications</subject><subject>Hypoglycemia - physiopathology</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk factors</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAURYMozjj6D0S60V3rSz-SxoUggzrCgBtdhzR51QzttCYdpf_elhbcuXqbcy_3HUIuKUQUKLvdRYVt2k8VxQBpBCICoEdkSUUGIQPgx2QJPEvCJInjBTnzfgcAGUvyU7KgWZYLYPGSxJu-bT6qXmNtVWD3Qde3GMSBsarADv1doALtbGe1qgKH3xZ_zslJqSqPF_Ndkfenx7f1Jty-Pr-sH7ahTgR0ITVlKgwqw7gygieUo8qLVKdapIVhWNKCIVM808iRoRYKNI9FVoIANJAnK3Iz9bau-Tqg72RtvcaqUntsDl4yThkIzgcwnUDtGu8dlrJ1tlaulxTk6Eru5ORKjq4kCDm4GmJXc_-hqNH8hWY5A3A9A8oP75dO7bX1fxwb1Yqx6H7icLAxGHLSa4t7jcY61J00jf1_yS8hf4i_</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Murata, Glen H.</creator><creator>Duckworth, William C.</creator><creator>Hoffman, Richard M.</creator><creator>Wendel, Christopher S.</creator><creator>Mohler, M. Jane</creator><creator>Shah, Jayendra H.</creator><general>Elsevier SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Hypoglycemia in type 2 diabetes: a critical review</title><author>Murata, Glen H. ; Duckworth, William C. ; Hoffman, Richard M. ; Wendel, Christopher S. ; Mohler, M. Jane ; Shah, Jayendra H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1df49dead67ad97317ea8b4c4c94bd6ef1b6e6a75ce7e6ec9a0c7295f090ed083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Circadian Rhythm - physiology</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetes mellitus, type II</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - blood</topic><topic>Hypoglycemia - complications</topic><topic>Hypoglycemia - physiopathology</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murata, Glen H.</creatorcontrib><creatorcontrib>Duckworth, William C.</creatorcontrib><creatorcontrib>Hoffman, Richard M.</creatorcontrib><creatorcontrib>Wendel, Christopher S.</creatorcontrib><creatorcontrib>Mohler, M. Jane</creatorcontrib><creatorcontrib>Shah, Jayendra H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murata, Glen H.</au><au>Duckworth, William C.</au><au>Hoffman, Richard M.</au><au>Wendel, Christopher S.</au><au>Mohler, M. Jane</au><au>Shah, Jayendra H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoglycemia in type 2 diabetes: a critical review</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>58</volume><issue>10</issue><spage>551</spage><epage>559</epage><pages>551-559</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><coden>BIPHEX</coden><abstract>Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability—an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.</abstract><cop>Paris</cop><pub>Elsevier SAS</pub><pmid>15589062</pmid><doi>10.1016/j.biopha.2004.09.001</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2004-12, Vol.58 (10), p.551-559
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_67160977
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Biological and medical sciences
Circadian Rhythm - physiology
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - physiopathology
Diabetes mellitus, type II
Humans
Hypoglycemia
Hypoglycemia - blood
Hypoglycemia - complications
Hypoglycemia - physiopathology
Hypoglycemic agents
Insulin
Medical sciences
Pharmacology. Drug treatments
Risk factors
title Hypoglycemia in type 2 diabetes: a critical review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A33%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoglycemia%20in%20type%202%20diabetes:%20a%20critical%20review&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Murata,%20Glen%20H.&rft.date=2004-12-01&rft.volume=58&rft.issue=10&rft.spage=551&rft.epage=559&rft.pages=551-559&rft.issn=0753-3322&rft.eissn=1950-6007&rft.coden=BIPHEX&rft_id=info:doi/10.1016/j.biopha.2004.09.001&rft_dat=%3Cproquest_cross%3E67160977%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67160977&rft_id=info:pmid/15589062&rft_els_id=S0753332204001465&rfr_iscdi=true